Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen

Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other analysts also recently commented on TSHA. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. UBS Group set a $11.00 target price on Taysha Gene Therapies in a research note on Thursday, December 4th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Chardan Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday. Finally, Wells Fargo & Company upped their price target on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.09.

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $4.40 on Friday. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $6.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The firm has a market capitalization of $1.21 billion, a PE ratio of -12.94 and a beta of 1.02. The company’s 50 day simple moving average is $4.63 and its 200 day simple moving average is $4.55.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million during the quarter, compared to the consensus estimate of $1.89 million. Taysha Gene Therapies had a negative return on equity of 62.55% and a negative net margin of 1,144.97%. As a group, equities research analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In related news, CEO Sean P. Nolan sold 41,312 shares of Taysha Gene Therapies stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $190,448.32. Following the transaction, the chief executive officer owned 2,908,257 shares of the company’s stock, valued at approximately $13,407,064.77. This trade represents a 1.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Kamran Alam sold 23,849 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $109,943.89. Following the sale, the chief financial officer owned 1,443,786 shares in the company, valued at approximately $6,655,853.46. The trade was a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 598,623 shares of company stock valued at $2,822,188 over the last three months. Company insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its holdings in shares of Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after acquiring an additional 4,607 shares during the period. ST Germain D J Co. Inc. boosted its stake in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after purchasing an additional 4,333 shares during the period. Oppenheimer Asset Management Inc. purchased a new position in Taysha Gene Therapies during the 4th quarter worth approximately $59,000. Guggenheim Capital LLC acquired a new stake in Taysha Gene Therapies during the 4th quarter valued at $61,000. Finally, Panagora Asset Management Inc. acquired a new stake in Taysha Gene Therapies during the 4th quarter valued at $64,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

More Taysha Gene Therapies News

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 2025 results topped expectations — reported EPS of ~$-0.087 vs. consensus ~$-0.096 and revenue of $5.49M well above estimates; management highlighted momentum on programs and financial results. Earnings Call Transcript (InsiderMonkey)
• Positive Sentiment: TSHA‑102 pivotal trial enrollment advancing and company says it’s on track to complete dosing in Q2 2026 with a 2026 BLA submission path — a clear clinical catalyst for future value. BLA Submission Path (MSN)
• Positive Sentiment: Analyst optimism picked up — Needham raised its price target to $12 (buy) and Chardan reaffirmed a $12 buy target, signaling sizable upside from current levels and likely contributing to increased attention. Analyst Coverage (Benzinga)
• Positive Sentiment: Company highlighted a strong cash position on the earnings call, which supports ongoing pivotal enrollment and development activity. Earnings Highlights (Yahoo Finance)
• Neutral Sentiment: Full earnings/management commentary and call transcripts are available from multiple outlets for investors who want the full details and Q&A. Transcript (Seeking Alpha)
• Negative Sentiment: Company remains unprofitable with a very negative net margin and negative return on equity; development risk and cash burn remain material risks until regulatory milestones or commercialization are achieved. Full Results & Corporate Update (GlobeNewswire)

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.